FDA approves Replimune melanoma therapy in combo with nivolumab
Go back to FDA approves Replimune melanoma therapy in combo with nivolumab| Rider Explorations, Inc. (NASDAQ: REPL) | Delayed: 12.87 -0.09 (0.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.96 | 52 Week High | $1.45 | |||
| Open | $13.15 | 52 Week Low | $0.50 | |||
| Day High | $13.40 | P/E | N/A | |||
| Day Low | $12.62 | EPS | $0.00 | |||
| Volume | 1,294,785 | |||||
